Company
Dublin
Every published round Allergan plc took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Allergan plc has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Allergan plc, as distinct from the investments it has made.
Companies Allergan plc has backed that another company then bought. An exit for the holding, not a deal Allergan plc did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Allergan plc is recorded as having been acquired. | ||||
Companies Allergan plc acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Allergan plc. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's blog republishes an AFR report on Azura Ophthalmics' encouraging phase 2 dry-eye results, recalling the Israel-founded biotech's US$38 million raised, among it a US$16 million round that Brandon Capital's fund co-led.
Azura Ophthalmics reports positive phase two results for its dry eye ointment and moves toward registration studies; the Brandon Capital-backed biotech has raised US$38 million, including a US$16 million round co-led by MRCF.
Anniversary profile of incubator Cicada Innovations' two decades, telling portfolio biotech Elastagen's story: its tropoelastin work, Series A backing, a government grant, and its 2018 sale to Allergan.
Also GBS Ventures·GBS Ventures
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily
Sydney-based tropoelastin biotech Elastagen agreed to an Allergan takeover offering US$95 million upfront plus contingent payments; the GBS Ventures-backed company previously drew MDF and federal grant funding.
Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Startup Daily·Startup Daily·Startup Daily